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Abstract
Purpose: BCR-ABL kinase domain (KD) mutations account for 50-90% of the imatinib resistance observed in patients of
CML-chronic phase. In CML-CP patients receiving imatinib first-line, mutation analysis is recommended in case of failure or
suboptimal response using European LeukemiaNet (ELN) criteria. The present study was carried out at a tertiary oncology centre
in south India to assess which mutations accounted for resistance to imatinib among patients of chronic phase CML being treated
with imatinib. Methods: This was a retrospective observational study. We analyzed patients who were tested for imatinib re-
sistance mutation in view of suboptimal responses while on imatinib or imatinib failure. Direct sequencing of the BCR-ABL
transcript by the Sanger method was used for IRMA testing. Results: Out of 120 tested for IRMA, 36 (30%) had detectable mu-
tations. We observed a higher frequency of mutations at amino acids T315, F359 and M351T. Conclusions: Among the patients
who were tested for imatinib resistance mutation in view of suboptimal responses while on imatinib or imatinib failure, 30% had
IRMA +ve mutations. The high incidence of imatinib resistance in present study may be attributed to the fact that our patients
were given higher dose of imatinib (600 mg), if they failed to achieve CCyR at 12 months or CHR at 3 months as they could not
afford second generation TKIs.
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Introduction
Chronic myeloid leukemia (CML) is a myeloproliferative
disorder characterized by the presence of the Philadelphia
(Ph) chromosome resulting from the reciprocal translocation
t (9; 22) (q34; q11).1, 2 The molecular consequence of this
translocation is the generation of the BCR-ABL fusion gene,
which encodes a constitutively active protein tyrosine kinase.
Typically, CML has 3 clinical phases: chronic stable phase,
accelerated phase and blast crisis phase with 90% of patients
being diagnosed in the chronic phase. The standard treatment
of choice in chronic stable phase has been imatinib mesylate
400 mg OD. Imatinib mesylate is tyrosine kinase inhibitor
that inhibits the abnormal bcr-abl tyrosine kinase created by
the Philadelphia (Ph1) chromosome translocation abnormal-
ity. Imatinib inhibits proliferation and induces apoptosis in
cells positive for BCR/ABL.3-5
With 5 years of follow-up, the overall survival of patients
randomized to imatinib as initial therapy is 89% and with 8
years, it is 85%.6, 7 Second generation tyrosine kinase inhibi-
tors like Nilotinib and Dasatinib are also approved for first
line treatment in chronic phase CML and have shown better
cytogenetic and molecular responses and improvements in
progression-free survival as compared to Imatinib.8, 9 How-
ever considering their high cost, imatinib still remains the
gold standard for frontline treatment of CML, especially in
low income countries.
Although imatinib is a major breakthrough in treatment of
chronic phase CML, every third or fourth patient has to come
off this therapy due to resistance or intolerance. BCR-ABL
kinase domain (KD) mutations account for 50-90% of the
imatinib resistance observed in patients of CML-CP.10
Till-date, more than 90 discrete resistance conferring point
mutations at 57 residues in the ABL kinase have been docu-
mented.11 The present study was carried out at a tertiary
oncology centre in south India to assess which mutations
accounted for resistance to imatinib among patients of
chronic phase CML being treated with imatinib.
Methods and Materials
This was a retrospective observational study. We analyzed
patients who were tested for imatinib resistance mutation in
view of suboptimal responses while on imatinib or imatinib
failure (loss of achieved milestones). Responses were being
assessed using ELN 2009 guidelines for management of
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CML.12 Complete haematologic response (CHR) was defined
as white blood count < 10× 109 /L; basophils <5%; no myelo-
cytes, promyelocytes, myeloblasts in the differential; platelet
count <450 × 109 /L and no palpable spleen. Major cytogenetic
response (MCyR) was defined as 0% - 35% Ph+ metaphases in
bone marrow aspirates. Complete CyR (CCyR) was defined as
no Ph+ metaphases, partial CyR (PCyR) was defined as 1% to
35% Ph+ metaphases, minor CyR was defined 36% to 65%
Ph+ metaphases, minimal CyR was taken with 66% to 95%
Ph+ metaphases and presence of >95% Ph+ metaphases con-
firmed no CyR. Complete molecular response was considered
with undetectable BCR-ABL messenger ribonucleic acid
transcript by real time quantitative and/or nested polymerase
chain reaction in two consecutive blood samples of adequate
quality and major molecular response (MMolR) was defined
as ratio of BCR-ABL to ABL≤ 0.1% on the international scale.
Response was considered as optimal in patients who achieved
CHR and at least minor CyR at 3 months, PCyR at 6 months,
CCyR at 12 months and MMolR at 18 months (Table 1 shows
response definitions). IRMA was done if patients failed to
achieve CHR at 3 months or CcyR at 18 months or if they had
loss of CHR/MMolR/ progression to accelerated phase at any
time (Table 2 shows patient criteria for IRMA).















































Abbreviation: CHR = Complete hematologic response; CyR = Cyto-
genetic response; PCyR = Partial cytogenetic response; CCyR =
Complete cytogenetic response; CMolR = Complete molecular re-
sponse; MMolR = Major molecular response.
TABLE 2: Patient criteria for IRMA.
Indication for IRMA Number of patients ( n= 36)
Failure to achieve CHR at 3 months 4
Failure to achieve CCyR at 18
months
10
Loss of CHR 11





Between January 2007 and January 2013, a total of 120 pa-
tients were tested for IRMA. Direct sequencing of the
BCR-ABL transcript by the Sanger method was used for
IRMA testing.13 Out of 120 patients, 84 patients did not have
any mutations. Rest of the 36 patients various mutations
rendering them resistant to imatinib (Table 3). Among these
36 patients, 11 patients had loss of CHR; 5 patients had loss of
MMolR; 4 patients had failure to achieve CHR at 3 months;
10 patients had failure to achieve CCyR at 12 months and 6
patients had progression to accelerated phase/ blast crisis. We
observed a higher frequency of mutations at amino acids
T315, F359 and M351T. In contrast to GIMEMA study we
had low frequency of M244V, Y253H and E255V.14
TABLE 3: Mutations detected by IRMA in present study.



















The present study was done to assess which mutations ac-
counted for resistance to imatinib among patients of chronic
phase CML being treated with imatinib. Out of 120 patients
tested for IRMA, nearly one-third (30%) had mutations de-
tected by IRMA. Our study results are in parallel with other
reported study in India in which 29 out of 90 (32.2%) patients
had detectable KD mutations.14 A considerably higher per-
centage of mutations (43%) was reported in the GIMEMA
study.15 The lower frequency of mutations in our study as
compared to GIMEMA study may be attributed to the fact
that while our study primarily focused on CP patients, the
GIMEMA study had patients from all stages of CML. We
observed a higher frequency of mutations at amino acids
T315, F359 and M351T. In contrast to GIMEMMA study we
had low frequency of M244V, Y253H and E255V.
Apart from imatinib, specific mutation types are also closely
associated with resistance to 2nd generation TKIs and this
information is useful in directing the choice of TKI after
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imatinib failure. (Table 4) Resistance to dasatinib often man-
ifests as mutations at amino acids 299 (V299L), 315 (T315I)
and 317 (F317 L/I) and resistance to nilotinib preferentially
results from mutations such as G250E, Y253H, E255K, T315I,
or F311I.16
TABLE 4: Selection of therapy following particular mutation.
Type of mutation Appropriate therapeutic option







Any other mutation High dose imatinib/nilotinib/dasatinib
Conclusion
Among the patients who were tested for imatinib resistance
mutation in view of suboptimal responses while on imatinib
or imatinib failure, 30% had IRMA +ve mutations. The high
incidence of imatinib resistance in present study may be
attributed to the fact that our patients were given higher dose
of imatinib (600mg), if they failed to achieve CCyR at 12
months or CHR at 3 months as they could not afford second
generation TKIs.
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